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Abstract: Pancreatitis in Systemic Lupus Erythematosus  (SLE) is a rare, but life threatening  complication.  We aimed to 
study the characteristics  and treatment outcome of SLE patients with acute pancreatitis in comparison with those with 
abdominal pain due to causes other than pancreatitis. Records of SLE patients admitted in our ward with pain abdomen 
between January 2008 and July 2010 were studied retrospectively. Of 551 SLE in-patients during the study period, 28 (5%) 
had abdominal pain and 11 (2%)  of  them  were  diagnosed  to have  acute  pancreatitis.  Five  of  the 11  patients  had  severe  
pancreatitis  and  6 had  mild pancreatitis. Seizures, arthritis and lack of prior use of steroids were significantly  more 
common in patients with pancreatitis as compared to those with abdominal pain of non pancreatic origin. Seizure occurred 
more often in severe pancreatitis group as compared to mild pancreatitis. There was no difference in prevalence of lupus 
anticoagulant and anticardiolipin antibody (40%) between SLE patients with pancreatitis and those with other causes of 
abdominal pain. Conclusion: Association of pancreatitis in our cohort of SLE patients include withdrawal of maintenance 
dose of  steroids, seizures and arthritis in univariate analysis. However there was no independent predictor of this 
complication in our study. 
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INTRODUCTION 
  Pancreatitis in systemic lupus erythematosus (SLE) is a rare 
but serious complication. Less than 200 cases have been 
reported in literature with an annual incidence of 2.3/1000 SLE 
patients [1, 2]. We report our experience on profile and 
treatment outcome of SLE patients with acute pancreatitis and a 
comparison of these with patients presenting with abdominal 
pain due to causes other than pancreatitis. 
PATIENTS AND METHODS 
  Records of SLE inpatients admitted with pain abdomen 
between 2008 to 2010 were studied retrospectively. All patients 
had fulfilled ACR 1997 revised classification criteria [3]. 
Details of demography, clinical features, SLE disease activity 
assessment (SELENA SLEDAI), laboratory parameters, 
imaging studies and management were noted [4]. Patients were 
categorized into those with abdominal pain due to pancreatitis 
and those with pain of non pancreatic etiology. Diagnosis of 
acute pancreatitis was made in the presence of abdominal pain 
or tenderness characteristic of pancreatitis, with at least 2 fold 
elevation of serum pancreatic enzymes i.e. serum amylase or 
lipase with or without imaging features [5]. Those with 
pancreatitis were further sub-classified into mild and severe 
subsets using Atlanta criteria, 1992 [6]. 
  Data was analyzed using SPSS-version 15. Fischer’s exact 
test was used to compare the two groups. The p value of <0.05 
was considered statistically significant. 
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RESULTS 
  Among 551 SLE patients admitted during the study 
period (data retrieved from our SLE database), 28 (5%) had 
presented with abdominal pain and 11 (2%) of them were 
diagnosed to have acute pancreatitis. Five of these 11 
patients had severe pancreatitis and 6 had mild pancreatitis. 
  Causes of abdominal pain of non pancreatitis origin 
included mesenteric ischemia, diagnosed clinically by 
characteristic abdominal pain and normal pancreatic 
enzymes in 1, probable intestinal vasculitis in 2, blood 
culture proven septicemia in 1, post surgery subacute 
obstruction due to intestinal adhesions in 1, acute 
gastroenteritis in 1 and no identifiable causes in 11 patients. 
Pancreatitis was ruled out in these 17 patients by absence of 
characteristic abdominal pain and/or by lack of elevated 
levels of pancreatic enzymes which were measured in 8 out 
of these 17 patients. 
  Majority of patients were females (26/28) and mean age 
was 26.7 ± 6.7 years. The median disease duration of SLE in 
patients with pancreatitis was 12 (range 2 - 72) months. 
None of the patients with pancreatitis had history of diabetes, 
alcoholism and cholelithiasis. Serum calcium and 
triglyceride levels were measured in 8/11 and 6/11 patients 
with pancreatitis respectively, but none of them had 
hypercalcemia or triglyceride levels more than 500mg/dl. No 
patient with pancreatitis was on azathioprine within the 
preceding 3 months. 
  A comparison of salient clinical features and lab 
parameters of patients with pancreatic and non pancreatic 
abdominal pain is listed in Table 1. 
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DISCUSSION 
  Articular involvement and occurrence of generalized tonic 
clonic seizures were significantly more common in patients with 
pancreatitis. This could be explained by high SLE disease 
activity in these patients. Other factors contributing to higher 
frequency of seizures in these patients could be electrolyte 
imbalance, antiphospholipid antibody syndrome or renal failure. 
Though 40% of our SLE patients with pancreatitis tested 
positive for antiphospholipid antibodies i.e. Lupus anticoagulant 
(LA) or Anticardiolipin antibody (aCLA), this frequency was 
not significantly different from that in patients with abdominal 
pain of non pancreatic origin, similar to that reported in earlier 
series [7]. None of our patients with pancreatitis had psychosis 
and only one had skin rash suggestive of cutaneous vasculitis, 
which was less frequent than reported incidence in series by 
Makol et al., [7]. 
  Lack  or withdrawal of prior steroid usage was also 
significantly associated with pancreatitis (7/11 vs 4/17, p< 0.05) 
in our series. Moreover , withdrawl of low dose maintenance 
steroid therapy was more often seen in severe as compared to 
mild pancreatitis (4/6 vs 0/5, p= 0.061). These associations 
could again reflect relapse of disease activity due to suboptimal 
therapy. The association of high SLE disease activity with bad 
outcome in pancreatitis has already been reported in a previous 
study [8]. 
  A multivariate analysis was done for independent 
predictors for pancreatitis, using the above three items found 
significant in univariate analysis and it did not reveal any 
significance probably due to smaller number of patients. 
Once pancreatitis was diagnosed, all our patients were 
treated with high dose steroids irrespective of severity status 
of pancreatitis. One patient was given anticoagulation in 
addition, due to moderately positive lupus anticoagulant and 
deep vein thrombosis. 
  Four patients (36%) had adverse outcome in the form of 
fatality in 2 and multiorgan dysfunction requiring ventilatory 
support in the remaining two. This figure is higher than that in 
other studies, which could possibly be explained by higher 
infection rate in our patients [2, 7, 9]. 
  In summary, pancreatitis was rare (2%) in our cohort of 
inpatients with SLE. Seizures, arthritis and discontinuation of 
maintenance dose of steroids were significantly more common 
in patients with pancreatitis, when compared to those with 
abdominal pain of non pancreatic origin. Occurrence of seizure 
went hand in hand with severity of pancreatitis. Forty percent 
of SLE patients with pancreatitis had antiphospholipid 
antibodies, similar to that in SLE patients with other causes of 
abdominal pain. 
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Table 1.  A Comparison of Salient Clinical Features and Lab Parameters of Patients 
 
Parameters   Abdominal Pain of Non Pancreatic Origin   Abdominal Pain Due to Pancreatitis 
Cutaneous involvement  3/17  6/11 
Articular involvement   4/17  9/11 * 
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Proteinuria (24 hr urine protein > 500mg)  11/15  4/10 
Elevated creatinine (>1.4 mg/dl)  1/11  5/11 
Low C3 (< 90 mg/dl)  11/15  11/11 
Low C4 (< 10mg/dl)  8/15  10/11 
Positive LA by dRVVT test  7/8  4/10 
Positive aCLA (> 12 U/ml)  6/13  4/10 
Mean SLEDAI  15±12  22 ± 11 
GTCS: generalized tonic clonic seizure, LA: lupus anticoagulant, ACLA : anticardiolipin antibody. 
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